argenx Reports Full Year 2023 Financial Results and Provides Fourth Quarter Business UpdateGlobeNewsWire • 02/29/24
argenx to Report Full Year 2023 Financial Results and Fourth Quarter Business Update on February 29, 2024GlobeNewsWire • 02/22/24
argenx Announces FDA Acceptance of Supplemental Biologics License Application with Priority Review for VYVGART Hytrulo in Chronic Inflammatory Demyelinating PolyneuropathyGlobeNewsWire • 02/20/24
argenx: Upgrading To 'Strong Buy' On Vyvgart's Q4 Sales, Empasiprubart Data, Pipeline ExpansionSeeking Alpha • 02/01/24
argenx Announces Approval of VYVDURA® (efgartigimod alfa and hyaluronidase-qvfc) Injection for Subcutaneous Use in Japan for Generalized Myasthenia GravisGlobeNewsWire • 01/18/24
INVESTOR ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against argenx SE and Encourages Investors with Losses to Contact the FirmAccesswire • 01/17/24
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against argenx SE and Encourages Investors with Losses to Contact the FirmAccesswire • 01/12/24
IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces it is Investigating Claims Against argenx SE and Encourages Investors with Losses to Contact the FirmAccesswire • 01/11/24
INVESTOR ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against argenx SE and Encourages Investors with Losses to Contact the FirmAccesswire • 12/28/23
ONGOING INVESTOR ALERT: The Schall Law Firm Announces it is Investigating Claims Against argenx SE and Encourages Investors with Losses to Contact the FirmAccesswire • 12/20/23
argenx Reports Topline Results from ADDRESS Study of Efgartigimod SC in PemphigusGlobeNewsWire • 12/20/23
Argenx Stock Crashes On An Unexpected Failure For Its Biggest DrugInvestors Business Daily • 11/28/23